By Gwendolyn Wu
Published October 6, 2026
In a move that sends a powerful signal of confidence to the global life sciences sector, Netherlands-based venture firm Forbion has successfully closed a landmark $2.6 billion (2.3 billion euros) fundraising round. This infusion of capital, spread across two distinct vehicles—Forbion Growth Opportunities IV and Forbion Ventures Fund VIII—represents the firm’s largest capital raise to date.
The announcement arrives at a pivotal juncture for the European biotechnology industry, which has struggled to maintain parity with the rapid pace of innovation and capital deployment seen in the United States and China. By securing these funds, Forbion is positioning itself as a vital bulwark against a persistent capital crunch, aiming to bolster a pipeline of startups that are increasingly finding themselves at a disadvantage compared to their international peers.
The Anatomy of the Fundraise: Powering the Pipeline
Forbion’s latest financial success story is built on the strength of two complementary investment vehicles. The firm has confirmed that these funds provide the "capacity" to support up to 30 early-to-mid-stage companies, with a focus on high-impact therapeutic development.
The deployment of this capital is already well underway. Recent strategic investments highlight the firm’s diverse portfolio, including backing for Sling Therapeutics and the immuno-oncology innovator Solstice Oncology. By diversifying across these stages—from early venture-backed startups to late-stage growth opportunities—Forbion is crafting a strategy that spans the entire lifecycle of drug development.
The list of institutional backers underscores the prestige and trust Forbion has cultivated over the years. Major players such as Dutch pension managers MN and PGGM, the Kauffman Foundation, Germany’s KfW Capital, and pharmaceutical giant Eli Lilly have all participated in the raise. With this injection of capital, Forbion now oversees a staggering 7.5 billion euros in assets under management (AUM), cementing its status as Europe’s premier venture firm exclusively dedicated to life sciences.
Chronology of Growth: From Modest Roots to Market Leader
To understand the magnitude of this achievement, one must look at Forbion’s trajectory. Since its inception, the firm has been a quiet engine behind European medical innovation, having supported 142 companies. Perhaps more tellingly, the firm has shepherded 21 drugs or essential medical technologies from the lab bench to the commercial market.
- Pre-2022: Forbion establishes itself as a reliable partner for early-stage life science ventures, focusing on the highly specialized needs of the Dutch and broader European biotech ecosystem.
- 2024: The firm announces a landmark $2.2 billion fundraise, signaling an aggressive expansion in its capacity to handle larger, more complex clinical trials.
- 2022–2026: A period of intense activity. During this four-year span, Forbion publicly announced at least 55 investments, establishing itself as one of the most consistent and active investors in the global biopharmaceutical sector.
- October 2026: The current $2.6 billion raise is finalized, exceeding the firm’s original targets and signaling strong investor appetite for high-quality European biotech assets.
This growth has been marked by a series of high-profile exits. The firm’s portfolio companies have frequently become the targets of major pharmaceutical acquisitions. Recent examples include the purchase of Capstan Therapeutics by AbbVie, the acquisition of Mariana Oncology by Novartis, and the buy-out of Aiolos Bio by GSK. Furthermore, the firm has seen successful public market entries, such as the IPO of MapLight Therapeutics, demonstrating that despite the market’s turbulence, Forbion’s curation remains top-tier.
Supporting Data: An Industry in Search of Capital
The necessity of Forbion’s latest fund is best understood through the lens of the current economic environment. Venture capital for biotech has become increasingly bifurcated. While top-tier firms in the U.S. continue to command billions in funding, the European landscape has faced a more restrictive environment.
Forbion’s internal data, paired with independent tracking from BioPharma Dive, reveals that the firm has acted as a critical counter-cyclical force. In a market often characterized by a "general shortage of capital," as described by Forbion co-founder and managing partner Sander Slootweg, the firm provides the "dry powder" necessary to prevent promising research from stalling due to funding gaps.
The firm’s consistent performance is not merely a matter of asset accumulation; it is a testament to the vetting process required to identify which companies can survive the "valley of death"—the period between early discovery and clinical validation. By maintaining a robust balance sheet, Forbion ensures that its portfolio companies can weather prolonged regulatory reviews and the volatile nature of clinical trials.
Official Responses and Strategic Vision
The leadership at Forbion has been vocal about the necessity of this capital raise in the current political and economic climate. Sander Slootweg emphasized that the firm’s success is intrinsically tied to its role as an enabler of innovation.
"Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," Slootweg stated in the official announcement. This sentiment is echoed by the institutional investors who continue to bet on Forbion, viewing the firm as a reliable bridge between European research excellence and global commercialization.
However, the firm’s leadership is also acutely aware of the broader systemic headwinds. While Forbion is thriving, the European biotech ecosystem as a whole is experiencing a moment of reckoning. The firm’s ability to raise capital serves as a beacon of success, but it also highlights the lack of similar scale in other European funds, which often leave startups searching for U.S.-based venture capital or acquisition to survive.
Implications: The "Alarm Bells" of European Biotech
The success of Forbion stands in sharp contrast to the warnings issued by industry leaders just one month ago. In a widely publicized open letter, nine prominent board chairs of European biotech companies called for urgent policy interventions. Their argument is stark: Europe has historically treated the pharmaceutical industry "as a cost to suppress rather than one of the best investments a government can make."
The implications of this stance are twofold:
- The Clinical Exodus: As European nations tighten their budgets, the continent has seen a decline in the total share of global clinical trials. This shifts the focus of R&D to jurisdictions with more favorable regulatory frameworks and faster timelines, such as China and the United States.
- The Regulatory Gap: There is a growing consensus that while European science remains world-class, the regulatory and commercial pathways are fragmented. China, in particular, has utilized aggressive government support and streamlined regulatory paths to lure startups away from Europe, creating a competitive disadvantage that is becoming increasingly difficult to bridge.
The nine executives who penned the open letter noted that "Europe’s alarm bells are ringing." They argue that without a concerted effort to harmonize regulatory standards and incentivize local investment, the region risks losing its intellectual property to foreign competitors who are better equipped to fund the transition from innovation to market.
Conclusion: A Bulwark for the Future
Forbion’s $2.6 billion achievement is more than a successful business deal; it is a lifeline for European science. As the firm prepares to deploy its record-breaking capital, the eyes of the global biotech industry will be watching to see which companies are selected for support.
For European policymakers, Forbion’s success serves as both a validation of the talent pool within the EU and a rebuke of the current funding climate. If the continent wishes to compete in the high-stakes world of modern medicine, it must find a way to replicate the scale of Forbion’s success across a wider range of institutions.
For now, Forbion stands as a singular, powerful force. With $7.5 billion in assets and a track record of translating complex biological science into life-saving commercial products, the firm is doing more than just investing—it is fighting to keep the heart of European biotech beating. As the industry moves into the latter half of the decade, the ability of firms like Forbion to bridge the gap between "good science" and "commercial reality" will determine whether Europe remains a center of medical discovery or becomes a mere observer in the global biopharmaceutical revolution.
About the Author
